__timestamp | Regeneron Pharmaceuticals, Inc. | Veracyte, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 205018000 | 16606000 |
Thursday, January 1, 2015 | 392709000 | 21497000 |
Friday, January 1, 2016 | 299694000 | 25462000 |
Sunday, January 1, 2017 | 397061000 | 28195000 |
Monday, January 1, 2018 | 434100000 | 33078000 |
Tuesday, January 1, 2019 | 782200000 | 36523000 |
Wednesday, January 1, 2020 | 1119900000 | 41455000 |
Friday, January 1, 2021 | 2437500000 | 74400000 |
Saturday, January 1, 2022 | 1560400000 | 101582000 |
Sunday, January 1, 2023 | 1815800000 | 112903000 |
Monday, January 1, 2024 | 1970500000 |
Unleashing insights
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Regeneron Pharmaceuticals, Inc. and Veracyte, Inc. have shown distinct trajectories in their cost of revenue from 2014 to 2023. Regeneron, a leader in the field, has seen its cost of revenue grow by approximately 785% over this period, peaking in 2021. In contrast, Veracyte's cost of revenue increased by about 580%, reflecting its strategic growth in the diagnostics sector. Notably, Regeneron's cost of revenue in 2023 was nearly 16 times that of Veracyte, highlighting its expansive operations. This data underscores the varying scales and strategies of these companies, offering insights into their operational efficiencies and market positioning. As the biotech industry continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders alike.
Cost of Revenue: Key Insights for Pfizer Inc. and Veracyte, Inc.
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Biogen Inc.'s Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Cytokinetics, Incorporated and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Perrigo Company plc and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Veracyte, Inc. and Mesoblast Limited